M&A Deal Summary |
|
|---|---|
| Date | 2024-06-27 |
| Target | Celsius Therapeutics |
| Sector | Life Science |
| Buyer(s) | AbbVie |
| Deal Type | Add-on Acquisition |
| Deal Value | 250M USD |
| Advisor(s) | Centerview Partners (Financial) Goodwin Procter (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 50,000 |
| Revenue | 54.3B USD (2023) |
AbbVie is a research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson's disease; and complications associated with chronic kidney disease and cystic fibrosis, among other health conditions. AbbVie was founded in 2012 and is based in North Chicago, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 11 of 11 |
| Sector (Life Science) | 11 of 11 |
| Type (Add-on Acquisition) | 10 of 10 |
| State (Massachusetts) | 3 of 3 |
| Country (United States) | 9 of 9 |
| Year (2024) | 2 of 2 |
| Size (of disclosed) | 8 of 9 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-25 |
Landos
Blacksburg, Virginia, United States Landos is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging its AI-based integrated computational platform, LANCE, the company has identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Its lead product candidate, BT-11, is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. Landos was founded in 2017 and is based in Blacksburg, Virginia. |
Buy | $138M |
